U.S. Markets closed

Agile Therapeutics, Inc. (AGRX)

NASDAQ Global Market - NASDAQ Global Market Delayed Price. Currency in USD
Add to watchlist
3.31-0.01 (-0.30%)
At close: 4:00PM EDT

3.33 +0.02 (0.70%)
After hours: 4:13PM EDT

People also watch
ALDXADHDAFMDAKBAARDX
Full screen
Previous Close3.32
Open3.32
Bid3.25 x 1000
Ask4.40 x 100
Day's Range3.25 - 3.35
52 Week Range1.82 - 8.15
Volume74,849
Avg. Volume265,728
Market Cap113M
Beta1.52
PE Ratio (TTM)-3.29
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research13 days ago

    AGRX: Raises $18.3 Million in Public Offering

    On July 27, 2017, Agile (AGRX) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its lead product, Twirla® (AG200-15), a once-weekly low–dose combination hormonal contraceptive patch. The FDA set the Prescription Drug User Fee Act (PDUFA) date as Dec. 26, 2017. Leading up to the PDUFA date, a number of pre-commercialization activities will take place, including a potential pre-approval inspection (PAI) of the manufacturing facility by the FDA for the company’s contract manufacturing organization (CMO) partner Corium.

  • 24/7 Wall St.20 days ago

    Agile Therapeutics Tanks on Secondary Offering

    Although Agile Therapeutics stock is down year to date, it’s actually more or less doubled since January. So now might be the time to take some profit.

  • Zacks Small Cap Research23 days ago

    AGRX: NDA for Twirla® Accepted by FDA; PDUFA is Dec. 26, 2017

    On July 27, 2017, Agile (AGRX) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its lead product, Twirla® (AG200-15), a once-weekly low–dose combination hormonal contraceptive patch. The FDA set the Prescription Drug User Fee Act (PDUFA) date as Dec. 26, 2017. Leading up to the PDUFA date, a number of pre-commercialization activities will take place, including a potential pre-approval inspection (PAI) of the manufacturing facility by the FDA for the company’s contract manufacturing organization (CMO) partner Corium.